Full Life is a leading provider of health and wellness solutions that leverage cutting-edge technology to deliver personalized care. With a focus on preventative health, the company offers a range of services including telehealth consultations, wellness tracking, and personalized fitness programs.

Full Life

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

Chengwei Capital

Yunion Health Investments

Sequoia Capital China

CD Capital

Junsan Capital

Kunlun Capital

Guanghua Wutong Fund

Prosperity7 Ventures

Dart Xia Yan Venture Capital

Junson Capital

Sky9 Capital

Summer Capital

Full-Life Technologies

Full-Life Technologies announced the recent achievement of its subsidiary “Full-Life Technology Europe” has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control (“FANC”), authorizing the construction and operation of this pivotal facility for producing therapeutic radioisotopes.

#FULLLIFE #NUCLEARPERMIT #FANC #RADIOISOTOPE 

Full-Life Technologies announced that preclinical data of 225Ac-FL-020 (a PSMA-targeted RDC program) will be presented in a Poster Session at the AACR (American Association for Cancer Research) Annual Meeting 2024, which will be held on Apr. 5th to 10th, 2024 in San Diego, CA.

#fulllife #AACR2024 #225Ac #RDC #PSMA

Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company and Eckert & Ziegler (ISIN DE0005659700, SDAX) today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). 

#FullLife #EckertZiegler #Ac225 #SupplyAgreement #radiotherapeutics

Check out Endpoints News' story with Julie Wu, CFO of Full-Life Technologies. 

#FullLife #Radioisotope #Actinium225 #PSMA

Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. 

#FullLife #SeriesB #Prosperity7 #Sky9Capital #SummerCapital #GuanghuaWutongFund #ChengweiCapital #HongShan #JunsonCapital #225Ac-FL-020 #UniRDC™

COM:FULL-LIFE

Full Life

Financials Not Available